NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

MaxCyte, Inc. (MXCT) Stock Analysis

MaxCyte, Inc. (MXCT) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MXCT

$1.47

+$0.04 (+2.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MXCT with… →

MXCT Key Statistics

As of Oct 21, 2026
Trading
Open
$1.43
Previous Close
$1.43
Day's Range
1.41–1.53
52-Week Range
0.64–1.81
Volume
1.42M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.49
Valuation
Market Cap
$151.71M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.89
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.34
Financials (FY)
Revenue (FY)
$33.03M−14.50%
Net Income (FY)
−$44.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
−114.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.21M
1-Year Return
−14.04%
Dividend and dates
Earnings Date
November 10, 2026
Avg Volume
840.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MXCT closed at $1.47, −14.04% over 1 year.

MaxCyte, Inc. (MXCT) has a market capitalization of $151.71M.

In fiscal 2025, MXCT reported revenue of $33.03M.

MXCT Stock Return by Calendar Year

MaxCyte, Inc. (MXCT) return since Jul 2021: what $10,000 became

1 year
$10,000 $8,596
−14.04%
5 years
$10,000 $1,389
−86.11%
Since Jul 2021
$10,000 $865
−91.35%

If you had invested $10,000 in MaxCyte, Inc. (MXCT) at the close on July 30, 2021, the earliest close on record here, it would have been worth $865 at the close on October 21, 2026: −91.35% in total, −37.40% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.16%
2025−62.74%
2024−11.49%
2023−13.92%
2022−46.42%
2021 (partial year)−40.06%

As of October 21, 2026.

MXCT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$33.03M−$44.63M−135.1%
2024$38.63M−$41.06M−106.3%
2023$41.29M−$37.92M−91.8%
2022$44.26M−$23.57M−53.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$33.03M$26.80M−$45.29M−$44.63M−135.1%
2024$38.63M$31.53M−$51.20M−$41.06M−106.3%
2023$41.29M$36.55M−$48.30M−$37.92M−91.8%
2022$44.26M$39.16M−$27.36M−$23.57M−53.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MXCT Valuation vs Medical Devices Median

Median of 145 stocks
MetricMXCTMedical Devices medianvs median
P/S ratio4.892.5393% above
Profit margin−114.77%−14.78%100.0 pts below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MaxCyte, Inc. (MXCT) is capitalised at $151.71M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 91.

The 52-week range on file runs from $0.64 to $1.81. MXCT last closed at $1.47 on October 21, 2026. That is +$0.04 (+2.80%) against the previous close. The latest close sits 128.62% above that 52-week low.

Financial Health

In fiscal 2025, MaxCyte, Inc. reported revenue of $33.03M. Against the prior fiscal year total of $38.63M, that is a change of −14.50%. The same year closed with a net loss of $44.63M. The reported profit margin is −114.77%. That is 100 percentage points below the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.34.

Across the 4 fiscal years on file, revenue moves from $44.26M in 2022 to $33.03M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 4.89 times revenue. On price-to-sales that is 93.14% above the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Over the trailing twelve months the total return is −14.04%. Measured over 5 years, that is −32.61% a year compounded. Beta against the wider market is reported at 1.49. Annualized volatility over the trailing 5 years is 69.45%.

Growth & Income

No dividend is on file for MXCT.

The strongest complete calendar year on file is 2024 at −11.49%; the weakest is 2025 at −62.74%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the total return is −5.16%.

Peer Comparison

MaxCyte, Inc. (MXCT) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MaxCyte, Inc. MXCT $151.71M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. MaxCyte, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Visit website →